CERO (CERo Therapeutics Holdings) Capex-to-Operating-Income : 0.00 (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

CERo Therapeutics Holdings's Capital Expenditure for the three months ended in Mar. 2025 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2025 was $-5.11 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

CERo Therapeutics Holdings Capex-to-Operating-Income Historical Data

The historical data trend for CERo Therapeutics Holdings's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Capex-to-Operating-Income Chart

CERo Therapeutics Holdings Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Capex-to-Operating-Income

CERo Therapeutics Holdings Quarterly Data
	Dec21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Capex-to-Operating-Income	Get a 7-Day Free Trial							-	-	-	-	-

Competitive Comparison of CERo Therapeutics Holdings's Capex-to-Operating-Income

For the Biotechnology subindustry, CERo Therapeutics Holdings's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CERo Therapeutics Holdings's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CERo Therapeutics Holdings's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where CERo Therapeutics Holdings's Capex-to-Operating-Income falls into.

Save Embed

;

Save Embed

;

CERo Therapeutics Holdings Capex-to-Operating-Income Calculation

CERo Therapeutics Holdings's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (0)	/	0
	=	N/A

CERo Therapeutics Holdings's Capex-to-Operating-Income for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (0)	/	-5.107
	=	N/A

CERo Therapeutics Holdings (NAS:CERO) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

CERo Therapeutics Holdings Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

CERo Therapeutics Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskings Way, Suite 230, South San Francisco, San Francisco, CA, USA, 94080

Website

https://www.cero.bio

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.